Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of ABBV-CLS-7262 in Healthy Volunteers
NCT06425003Phase 1Completed
- Sponsor
- Calico Life Sciences
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fosigotifator in leukoencephalopathy with vanishing white matter (VWM) and amyotrophic lateral sclerosis (ALS), sponsored by Calico Life Sciences. Primary endpoints: Number of Participants with Adverse Events (AEs) up to 30 days, Maximum observed concentration and 5 more. Started May 2024; status: completed.
02
Drugs
fosigotifator
03
Conditions
leukoencephalopathy with vanishing white matter (VWM)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06425003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425003.